Comparative Pharmacology
Head-to-head clinical analysis: STAPHCILLIN versus VERSAPEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: STAPHCILLIN versus VERSAPEN.
STAPHCILLIN vs VERSAPEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Semisynthetic penicillin; inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation, and activating autolytic enzymes.
Bactericidal; inhibits cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting peptidoglycan cross-linking.
1-2 g IV every 4-6 hours.
500 mg IV every 6 hours or 1 g IV every 8 hours for moderate infections; 2 g IV every 4 hours for severe infections.
None Documented
None Documented
0.5-1 hour in adults with normal renal function; prolonged to 2-4 hours in renal impairment. Infants: 1-2 hours.
0.5-1.0 hour (normal renal function); prolonged to 10-20 hours in anuria. Requires dose adjustment in renal impairment.
Primarily renal (70-90% as unchanged drug via glomerular filtration and tubular secretion); minor biliary excretion (<5%) and fecal elimination (<1%).
Renal: 60-70% unchanged via glomerular filtration and tubular secretion. Biliary: <10% excreted unchanged. Fecal: 20-30% as metabolites.
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic